Journal of Microbiology Immunology and Infection最新文献

{"title":"Components of cardiometabolic risk factors predict liver-related events in patients cured of hepatitis C Virus.","authors":"Wei-Fan Hsu, Hsueh-Chou Lai, Hung-Wei Wang, Sheng-Hung Chen, Wen-Pang Su, Hung-Yao Chen, Guan-Tarn Huang, Cheng-Yuan Peng","doi":"10.1016/j.jmii.2025.07.011","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.011","url":null,"abstract":"<p><strong>Background: </strong>The new nomenclature of steatotic liver disease (SLD) was proposed in June 2023. The effects of cardiometabolic risk factors (CMRFs) on liver-related events (LREs) in patients achieving chronic hepatitis C (CHC) eradication are unknown.</p><p><strong>Methods: </strong>This study recruited 1185 patients cured of CHC. CMRFs and alcohol consumption were clearly defined. Variables obtained at 12 or 24 weeks after direct-acting antiviral therapy (PW12) were used to identify the predictors of LREs.</p><p><strong>Results: </strong>A total of 562 patients (47.4 %) had metabolic dysfunction-associated SLD (MASLD), 96 (8.1 %) had MASLD with increased alcohol intake, 14 (1.2 %) had alcohol-related liver disease, 78 (6.6 %) had cryptogenic SLD, and 435 (36.7 %) had no SLD. Multivariable Cox regression analysis indicated that age, alcohol consumption, per CMRF (hazard ratio: 1.332, 95 % confidence interval: 1.094-1.621), posttreatment albumin level, alpha-fetoprotein level, and fibrosis-4 index >3.25 were independent predictors of LREs. Another multivariable analysis revealed that prediabetes and diabetes mellitus were predictors of LREs.</p><p><strong>Conclusions: </strong>The new fatty liver disease nomenclature of SLD was used to stratify the risk of LREs in patients achieving CHC eradication. The risk of LREs increased by 33 % per CMRF, and prediabetes or DM was a predictor of LREs.</p>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Taiwan's first successfully treated case of Candida auris-related bilateral leg complicated skin and soft tissue infection, osteomyelitis, and suspected endophthalmitis.","authors":"Yea-Yuan Chang, Chia-Wei Chang, Yung-Chen Chien, Chung-Shu Lin, Yung-Hsuen Hsu","doi":"10.1016/j.jmii.2025.07.012","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.012","url":null,"abstract":"","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and genomic insights into Acinetobacter parvus: A rare pathogen with low antibiotic resistance and potential clinical implications.","authors":"Qin Tang, Daili Zhou, Fei Yan, Lu Lin, Juan Fang, Xingchen Bao","doi":"10.1016/j.jmii.2025.07.010","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.010","url":null,"abstract":"<p><strong>Research background: </strong>Traditionally seen as an environmental bacterium, Acinetobacter parvus has rarely been studied in clinical settings. Its role in human infections remains unclear, particularly in vulnerable populations. This study explores its biological traits, antibiotic resistance, and genomic features through the first systematic analysis of strain ZDL0830, isolated from an immunocompromised patient with an abscess.</p><p><strong>Research methods: </strong>The strain was identified using MALDI-TOF MS and 16S rRNA sequencing. Its growth characteristics, Gram staining, and biochemical properties were analyzed with API 20NE and VITEK 2. Antibiotic susceptibility was tested across multiple drug classes using disk diffusion, Etest, and AutoMic i600. Whole-genome sequencing provided insights into its genetic makeup, with resistance and virulence genes identified through the CARD and VFDB databases. Phylogenetic relationships were assessed using 16S rRNA sequencing and ANI/DDH analysis.</p><p><strong>Key findings: </strong>The strain exhibited slow growth (visible colonies after 72 h) and limited metabolic activity but shared core pathways with other Acinetobacter species. It was susceptible to β-lactams (e.g., cefoperazone/sulbactam, meropenem) and aminoglycosides (amikacin), but resistant to ciprofloxacin and intermediately resistant to levofloxacin. Genomic analysis revealed only one resistance gene (APH_3-VIa) and virulence factors associated with biofilm formation (lpxC, bfmR) and motility (pilT, gspE1).</p><p><strong>Conclusion: </strong>This study sheds light on the clinical potential of Acinetobacter parvus, particularly in immunocompromised patients. While its low resistance profile allows for effective treatment, its ability to cause infections warrants further attention.</p>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maraviroc treatment for hospitalized participants with non-severe COVID-19 at risk of progression: a randomized, proof-of-concept clinical trial.","authors":"Carmen Gasca-Capote, José Manuel Lomas-Cabezas, Abraham Saborido-Alconchel, Cristina Moral-Turón, María Dolores Navarro, Antonio Ramos, Manuel Poyato-Borrego, Angela María Villalba, Inmaculada Rivas-Jeremías, Monserrat Domínguez, Julia Praena, José Miguel Cisneros, Luis F López-Cortés, Ezequiel Ruiz-Mateos","doi":"10.1016/j.jmii.2025.07.007","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.007","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic options for hospitalized people with COVID-19 remain limited, especially for people with non-severe COVID-19 at risk of progression. The anti-inflammatory role of maraviroc, a CCR5 antagonists, makes it a good candidate for therapeutic strategies for COVID-19.</p><p><strong>Methods: </strong>This was a proof-of-concept, phase II, parallel, open label clinical trial, to evaluate the safety and efficacy of maraviroc (300 mg, bid), CCR5 antagonist, combined with standard of care (SoC) treatment compared to SoC alone during 14 days, in hospitalized people with mild COVID-19 with pneumonia and ambient air oxygen saturation >94 %. Demographical, clinical, and analytical data were assayed at day 0, 7, 14 and 28.</p><p><strong>Results: </strong>Thirty-three participants were included, 17 in the control and 16 in the maraviroc group. The proportion of participants who experienced COVID-19 progression was 2.8 times higher in the control group than in the maraviroc group, with three participants admitted in intensive care unit versus none in the maraviroc group. The only variable associated with the time to severe COVID-19 progression was maraviroc treatment. The median time on oxygen therapy was 11 days in the control group, while the two participants in the maraviroc group had oxygen therapy for one and four days. Grade 3-4 events were only present in the control group. Maraviroc treatment was associated with a better neutrophil/lymphocyte ratio and lactate dehydrogenase, IL-6 and TNF-α levels at day 7.</p><p><strong>Conclusions: </strong>We observed a beneficial role of maraviroc in hospitalized participants with mild COVID-19 at risk of progression at admission.</p>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin 27 (IL-27) productions in the liver microenvironment confer an immunosuppressive role and enhance hepatitis B viral persistence.","authors":"Hsiu-Jung Liao, Lin-Ping Cheng, Yu-Ching Hsieh, Chien-Sheng Wu, Hung-Chih Yang, I-Tsu Chyuan, Ping-Ning Hsu","doi":"10.1016/j.jmii.2025.07.001","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.001","url":null,"abstract":"<p><strong>Background: </strong>Persistent chronic hepatitis B virus (HBV) infection leads to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. The immunosuppressive tissue microenvironment in the liver restricts the immune response, potentially facilitating persistent HBV infection. This study examined the expression of immunity-related factors in the liver in response to HBV.</p><p><strong>Methods: </strong>We performed gene expression profiling on mice subjected to HBV DNA hydrodynamic transfection to identify transcriptomic changes. The expression of IL-27 was validated through Western blotting, ELISA, and immunohistochemical staining. Liver macrophages in mice were depleted using clodronate-liposomes to evaluate their role in IL-27 production. IL-27 knockout mice were generated to examine the effects of IL-27 deficiency on CD8 T cell dysfunction and HBV persistence.</p><p><strong>Results: </strong>Transcriptomic analysis demonstrated that IL-27 is significantly induced in the liver in response to HBV DNA. The elevated levels of IL-27 are strongly correlated with HBV persistence and are linked to CD8 T cell dysfunction, characterized by increased expression of PD-1 and Tim-3, along with reduced IFN-γ production in liver-infiltrating T cells. Furthermore, depleting macrophage-lineage cells using clodronate-liposomes significantly reduces IL-27 production in the liver and promotes viral clearance. Additionally, mice with IL-27 deficiency exhibit enhanced HBV clearance and restored CD8 T cell function.</p><p><strong>Conclusions: </strong>Collectively, IL-27 is significantly induced by HBV in the liver, and its production is strongly associated with HBV persistence and CD8 T cell dysfunction. This highlights the immunosuppressive role of IL-27 in the liver microenvironment and suggests that IL-27 could serve as a potential therapeutic target for HBV infection.</p>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First documented case of primary cutaneous coccidioidomycosis in Taiwan.","authors":"Chih-Wei Liang, Kun-Mu Lee, Ming-Tzu Wu, Ya-Ting Chang, Yi-Ting Tseng, Shang-Yi Lin","doi":"10.1016/j.jmii.2025.07.009","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.009","url":null,"abstract":"","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma calprotectin as a severity biomarker in pediatric invasive Streptococcus pyogenes infections: insights from a multicenter immune profiling study during an outbreak.","authors":"José Avendaño-Ortiz, David Aguilera-Alonso, Concepción M Rodríguez, Jesús Oteo-Iglesias, Roberto Lozano-Rodríguez, Eduardo López-Collazo, Andrea López-Suárez, Victoria Rello-Saltor, Ana Belén Jimenez, Beatriz Jiménez, Rosa Del Campo, Rafael Cantón, Cristina Calvo, Jesús Saavedra-Lozano","doi":"10.1016/j.jmii.2025.07.008","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.008","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize the immune signature of pediatric invasive Streptococcus pyogenes infections (iGAS) and identify host biomarkers associated with disease severity.</p><p><strong>Methods: </strong>Plasma samples (n = 32) were collected during an iGAS outbreak from a multicentric Spanish pediatric cohort, including patients with iGAS (n = 19), S. pyogenes acute tonsillitis (n = 3), and healthy children/controls (n = 10). Patients were monitored and stratified based on the need of pediatric intensive-care unit (PICU). A panel of 56 soluble markers -including cytokines, chemokines, immune-checkpoints, antimicrobial peptides, growth factors, and vascular inflammation, myeloid and thrombosis markers- were quantified in plasma.</p><p><strong>Results: </strong>Regardless of disease severity, children with S. pyogenes infection exhibited a systemic inflammatory profile characterized by an upregulation of vascular inflammation markers. Patients with iGAS requiring PICU admission were mostly infected by emm1 S. pyogenes harboring speA and speJ genes and exhibited an immune profile characterized by alterations in CXCL10, IL-6, IL-10, IL-17A, sCD14, sCD40L, calprotectin, angiopoietin 2 and HGF. Area under the ROC curve analysis revealed that calprotectin and IL-6 exhibited the best classificatory performance for PICU admission (p < 0.01; AUC = 0.90 and AUC = 0.91, respectively), with an optimal Youden cut-off for calprotectin of 2753 ng/mL. A logistic regression model integrating both biomarkers and routine clinical parameters revealed an independent association between calprotectin levels and PICU admission.</p><p><strong>Conclusion: </strong>Pediatric iGAS is characterized by a complex immune landscape involving a combination of vascular and immune response mediators. Plasma calprotectin levels emerge as a promising severity biomarker, potentially aiding in the early identification of high-risk patients.</p>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of the monovalent XBB.1.5 COVID-19 vaccines: A systematic review and meta-analysis.","authors":"Hsin Ma, Yi-Yu Chen, Wei-Liang Shih, Yu-Chun Chen, Tzeng-Ji Chen, Chi-Tai Fang","doi":"10.1016/j.jmii.2025.07.002","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.002","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) remains a public health concern even after its pandemic status officially ended on May 5, 2023, when XBB became the globally predominant SARS-CoV-2 variant. Amid population immunity, the benefit of the monovalent XBB.1.5 vaccines remains uncertain.</p><p><strong>Methods: </strong>This systematic review searched PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials through November 30, 2024, for studies evaluating the effectiveness of XBB.1.5 vaccines in adults during the 2023-2024 season. Meta-analyses were conducted using a random-effects model (PROSPERO registration: CRD42024513730).</p><p><strong>Results: </strong>Twenty-one eligible studies, with a total of 53,396,781 participants, were included. Vaccine effectiveness (VE) in the first month post-vaccination was 52.9 % (95 % CI: 47.6 %-57.6 %) against SARS-CoV-2 infection, 64.4 % (95 % CI: 59.3 %-68.9 %) against COVID-19-related hospitalization, and 77.3 % (95 % CI: 67.1 %-84.3 %) against COVID-19-related death. However, by the fifth month, VE declined to 26.7 %, 52.3 %, and 69.4 %, respectively. Notably, against the JN.1 variant that replaced XBB in December 2023, VE against infection, hospitalization, and death dropped significantly by 47 % (from 53.7 % to 28.3 %), 32 % (from 67.8 % to 46.2 %), and 26 % (from 77.3 % to 57.1 %), respectively. VE against hospitalization in individuals aged >60 years was not inferior to that in those aged <60 years (57.2 % versus 49.2 %; subgroup difference, p = 0.24).</p><p><strong>Conclusion: </strong>XBB.1.5 vaccines provided substantial protection against severe COVID-19 outcomes in the 2023-2024 season prior to the emergence of the JN.1 variant. These findings underscore the need for updated COVID-19 vaccinations to maintain protection against evolving SARS-CoV-2 variants.</p>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronicity and quality of life in Chikungunya virus infection: a cross-sectional study in Barranquilla, Colombia.","authors":"Jorge Acosta-Reyes, Rafael Tuesca, Edgar Navarro-Lechuga, Brayan Bayona-Pacheco, Diego Viasus","doi":"10.1016/j.jmii.2025.07.005","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.005","url":null,"abstract":"<p><p>Chikungunya virus (CHIKV) infection is the second most widespread arboviral disease after dengue, and a significant number of patients suffer from a spectrum of chronic symptoms. Our objective was to estimate the prevalence of chronic CHIKV infection and its impact on the quality of life of patients. This cross-sectional study was carried out during the CHIKV epidemic in Colombia. For the diagnosis of CHIKV infection, clinical and laboratory criteria were used. Chronic CHIKV infection was defined as a persistence of symptoms after 3 months of the acute episode and health-related quality of life was measured using the Short Form- 36 Health Survey. We selected 290 patients with clinical criteria for CHIKV infection, 172 had positive IgG test anti-CHIKV and were analyzed in the study. The mean age of patients was 43.2 years (SD = 15.4), 128 (74.4 %) were female. Chronic CHIKV infection was documented in 149 (86.6 %, 95 %CI 80.9-91.1). The most frequent symptom was persistent join pain in 94.0 % and affected more frequently knees (67.8 %) and ankles (65.1 %). The SF-36 showed lower values in physical and mental summaries in chronic CHIKV infection compared with non-chronic disease (p value < 0.001). These results show that chronic CHIKV infection is common after an acute episode of CHIKV infection and has a significant impact on the physical and mental health of patients. Health systems must be prepared to adequately identify and care for this population.</p>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The novel pyridine-fused quinolinone PQ-L5 exhibits antibacterial effects and enhances β-lactam activity by targeting PBP2a in methicillin-resistant Staphylococcus aureus.","authors":"Wei Feng, Qian Yuan, Xiaowen Wang, Qianmei Wang, Ye Wei, Fengjun Sun","doi":"10.1016/j.jmii.2025.07.006","DOIUrl":"https://doi.org/10.1016/j.jmii.2025.07.006","url":null,"abstract":"<p><strong>Background: </strong>Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are becoming increasingly difficult to treat because of the resistance of this pathogen to multiple drugs and its ability to form biofilms. Therefore, the development of new antimicrobial agents to combat MRSA infections is urgently needed.</p><p><strong>Methods: </strong>We designed and synthesized a series of structurally novel pyridine-fused quinolinones via a one-pot method, and compound PQ-L5 which exhibited excellent antibacterial activity against gram-positive bacteria, especially MRSA strains was selected for further study. The bactericidal activity, synergistic antibacterial effect and antibiofilm activity of PQ-L5 were investigated, and then its in vitro cytotoxicity and in vivo anti-MRSA efficacy were evaluated.</p><p><strong>Results: </strong>PQ-L5 displayed rapid bactericidal activity without inducing resistance even after continuous passage. The mechanistic study revealed that PQ-L5 inhibited peptidoglycan biosynthesis by binding to PBP2a, disrupting the bacterial cell wall and ultimately resulting in bacterial death. Furthermore, PQ-L5 restored the susceptibility of MRSA to β-lactam antibiotics and could inhibit the biofilm formation of different MRSA strains at sub-MIC concentrations both alone and in combination with oxacillin. In addition, PQ-L5 had low hemolytic activity and cytotoxicity in vitro, and in a mouse skin tissue infection model, PQ-L5 alone or in combination with oxacillin at a low dose reduced the MRSA load in wounds and enhanced the process of wound healing.</p><p><strong>Conclusions: </strong>PQ-L5 might be a promising antimicrobial agent against MRSA infections and that the synergistic effect of PQ-L5 combined with β-lactams reduces the required dosages of these drugs and thus minimizes potential toxic side effects.</p>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}